Posts Tagged ‘Stemline Therapeutics’

Regenerative Medicine Deal Review: January

Author: Mark Curtis, 02/23/15

. Welcome to your deal review for the month of January. There was a mixed bag of news last month, which included financing activity, industry partnerships and research collaborations. The cell therapy tools industry was front and centre as NeoStem and Invetech struck up a deal to develop a closed, automated cell manufacturing unit for…Read more

Update from the clinic: January

Author: Mark Curtis, 02/19/15

. Welcome to your Update from the Clinic for the month of January. Pluristem and OncoMed reported preliminary efficacy data from early-stage trials, while the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) granted a number of Orphan Drug Designations for various cancer indications being developed by OncoMed, Stemline Therapeutics, and Kite…Read more

Update from the Clinic: December

Author: Mark Curtis, 01/13/15

. Welcome to your Update from the Clinic for the month of December. bluebird bio’s first four patients are transfusion-free after treatment with its gene therapy Lentiglobin. Fate Therapeutics’ hematopoietic stem cell-modulating technology ProHema seems to be on track to produce results in the clinic. bluebird bio (BLUE), which recently priced a common offering to…Read more

Update from the Clinic: July

Author: Mark Curtis, 08/18/14

. Welcome to your Update from the Clinic for the month of July. The cancer stem cell companies were back in the news last month. OncoMed initiated its ALPINE clinical trial of Tarextumab for pancreatic cancer, while Stemline Therapeutics announced an investigational new drug (IND) for SL-401 and initiation of clinical trials in two blood…Read more

Update from the Clinic: February

Author: Mark Curtis, 03/11/14

. Welcome to your update from the clinic for the month of February!  OncoMed is the leader in news this month with various Phase 1b trials for its cancer stem cell-targeting fusion protein. Immunocellular Therapeutics and StemCells Inc. file orphan drug designations with the European Medicines Agency and FDA for their respective cell therapies. Read…Read more

Update from the Clinic: January

Author: Mark Curtis, 02/04/14

. Welcome to your Update from the Clinic for the month of January! We start the year off with the German health authority approving Pluristem’s next generation GMP cell manufacturing facility. Neuralstem successfully, and safely, transplants NSI-556 cells directly into the brain of its first patient in a Phase 1/2 study. Meanwhile, OncoMed and StemCells…Read more